283 related articles for article (PubMed ID: 31807952)
21. Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.
Casida JE; Ford B; Jinsmaa Y; Sullivan P; Cooney A; Goldstein DS
Chem Res Toxicol; 2014 Aug; 27(8):1359-61. PubMed ID: 25045800
[TBL] [Abstract][Full Text] [Related]
22. Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation.
Legros H; Dingeval MG; Janin F; Costentin J; Bonnet JJ
Neurotoxicology; 2004 Mar; 25(3):365-75. PubMed ID: 15019299
[TBL] [Abstract][Full Text] [Related]
23. The rat rotenone model reproduces the abnormal pattern of central catecholamine metabolism found in Parkinson's disease.
Landau R; Halperin R; Sullivan P; Zibly Z; Leibowitz A; Goldstein DS; Sharabi Y
Dis Model Mech; 2022 Jan; 15(1):. PubMed ID: 34842277
[TBL] [Abstract][Full Text] [Related]
24. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
Lamensdorf I; Eisenhofer G; Harvey-White J; Nechustan A; Kirk K; Kopin IJ
Brain Res; 2000 Jun; 868(2):191-201. PubMed ID: 10854571
[TBL] [Abstract][Full Text] [Related]
25. Dihydroxyphenylacetaldehyde Lowering Treatment Improves Locomotor and Neurochemical Abnormalities in the Rat Rotenone Model: Relevance to the Catecholaldehyde Hypothesis for the Pathogenesis of Parkinson's Disease.
Khashab R; Gutman-Sharabi N; Shabtai Z; Landau R; Halperin R; Fay-Karmon T; Leibowitz A; Sharabi Y
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569897
[TBL] [Abstract][Full Text] [Related]
26. Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of α-Synuclein.
Werner-Allen JW; DuMond JF; Levine RL; Bax A
Angew Chem Int Ed Engl; 2016 Jun; 55(26):7374-8. PubMed ID: 27158766
[TBL] [Abstract][Full Text] [Related]
27. Aldehyde dehydrogenase inhibition generates a reactive dopamine metabolite autotoxic to dopamine neurons.
Doorn JA; Florang VR; Schamp JH; Vanle BC
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S73-5. PubMed ID: 24262193
[TBL] [Abstract][Full Text] [Related]
28. Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein.
Werner-Allen JW; Monti S; DuMond JF; Levine RL; Bax A
Biochemistry; 2018 Mar; 57(9):1462-1474. PubMed ID: 29394048
[TBL] [Abstract][Full Text] [Related]
29. N-Acetylcysteine Prevents the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.
Goldstein DS; Jinsmaa Y; Sullivan P; Sharabi Y
Neurochem Res; 2017 Nov; 42(11):3289-3295. PubMed ID: 28840582
[TBL] [Abstract][Full Text] [Related]
30. Characterization of Catecholaldehyde Adducts with Carnosine and l-Cysteine Reveals Their Potential as Biomarkers of Catecholaminergic Stress.
Crawford RA; Gilardoni E; Monroe TB; Regazzoni L; Anderson EJ; Doorn JA
Chem Res Toxicol; 2021 Oct; 34(10):2184-2193. PubMed ID: 34506109
[TBL] [Abstract][Full Text] [Related]
31. The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin.
Rooke N; Li DJ; Li J; Keung WM
J Med Chem; 2000 Nov; 43(22):4169-79. PubMed ID: 11063613
[TBL] [Abstract][Full Text] [Related]
32. Catechols in post-mortem brain of patients with Parkinson disease.
Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Basile MJ; Mash DC
Eur J Neurol; 2011 May; 18(5):703-10. PubMed ID: 21073636
[TBL] [Abstract][Full Text] [Related]
33. 3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease.
Burke WJ
Curr Drug Targets CNS Neurol Disord; 2003 Apr; 2(2):143-8. PubMed ID: 12769806
[TBL] [Abstract][Full Text] [Related]
34. Biogenic aldehyde(s) derived from the action of monoamine oxidase may mediate the antidipsotropic effect of daidzin.
Keung WM
Chem Biol Interact; 2001 Jan; 130-132(1-3):919-30. PubMed ID: 11306106
[TBL] [Abstract][Full Text] [Related]
35. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
Lima VA; do Nascimento LA; Eliezer D; Follmer C
ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158
[TBL] [Abstract][Full Text] [Related]
36. 3,4-Dihydroxyphenylacetaldehyde-Induced Protein Modifications and Their Mitigation by
Jinsmaa Y; Sharabi Y; Sullivan P; Isonaka R; Goldstein DS
J Pharmacol Exp Ther; 2018 Jul; 366(1):113-124. PubMed ID: 29700232
[TBL] [Abstract][Full Text] [Related]
37. Formation of large oligomers of DOPAL-modified α-synuclein is modulated by the oxidation of methionine residues located at C-terminal domain.
Coelho-Cerqueira E; de Araújo Correia Campos C; Follmer C
Biochem Biophys Res Commun; 2019 Feb; 509(2):367-372. PubMed ID: 30591215
[TBL] [Abstract][Full Text] [Related]
38. Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
Kumar VB; Hsu FF; Lakshmi VM; Gillespie KN; Burke WJ
Eur J Pharmacol; 2019 Feb; 845():65-73. PubMed ID: 30579934
[TBL] [Abstract][Full Text] [Related]
39. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases.
Burke WJ; Li SW; Chung HD; Ruggiero DA; Kristal BS; Johnson EM; Lampe P; Kumar VB; Franko M; Williams EA; Zahm DS
Neurotoxicology; 2004 Jan; 25(1-2):101-15. PubMed ID: 14697885
[TBL] [Abstract][Full Text] [Related]
40. 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis.
Li SW; Lin TS; Minteer S; Burke WJ
Brain Res Mol Brain Res; 2001 Sep; 93(1):1-7. PubMed ID: 11532332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
